New vaccine for renal cell carcinoma found to increase survival rates
July 30, 2012
by Bob Yirka
in Cancer
(Medical Xpress) -- Researchers working for German pharmaceutical company Immatics Biotechnologies GmbH, have outlined two successful outcomes for their multipeptide vaccine IMA901 in a paper theyve had published in the journal Nature Medicine. In it they describe how renal cell carcinoma (RCC) patients vaccinated with IMA901 experienced longer survival rates and how theyve also discovered key markers that they believe indicate which patients are most likely to benefit from the vaccine.
RCC, also known as hypernephroma, is the most common type of kidney cancer and survival rates for those who get it are low if the cancer metastases. Current treatment usually means removal of the cancerous tissue along with various forms of immunotherapy as radiation and chemotherapy are generally ineffective. Immunotherapy involves administering drugs that help the body identify cancerous cells as something that needs to be attacked and killed. To date, unfortunately, progress in this area of medicine has been slow, thus, the news that the vaccine developed my Immatics is showing some success is generating excitement in the cancer research world.
RCC vaccines are therapeutic, not preventative, hence they are only administered to people who have already been diagnosed. IMA901 was developed by noting the different antigens that come to exist on or around tumors as a result of the growth of cancerous cells under certain circumstances. The vaccine is made up of ten peptides that the research team has found cause stimulation of the immune system in patients that express the antigens theyve noted. That in turn causes the immune system to go on alert and to attack the tumors and hopefully kill them in the process.
IMA901 has currently gone through phase 1 and 2 clinical trials and is currently in phase 3. In the first two phases, the team found longer survival rates for the patients who volunteered to take part in the testing. Survival rates for those who undergo current treatment therapies are typically sixty to seventy percent for five years.
The team also detailed two serum biomarkers theyve discovered that they believe signal which RCC patients would be the most likely to benefit from IMA901, though they note that they wont know for sure how accurate they are until completion of phase 3 of their clinical trials.
More information: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nature Medicine (2012) doi:10.1038/nm.2883
Abstract
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02+ subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)+ regulatory T (Treg) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of Treg cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.
Journal reference:
Nature Medicine
© 2012 Medical Xpress
-
Researchers find papillary renal cell carcinoma unresponsive to sunitinib
May 28, 2010 |
not rated yet |
0
-
Novel brain tumor vaccine acts like bloodhound to locate cancer cells
Jan 05, 2012 |
not rated yet |
0
-
Cuba releases world's first lung cancer vaccine
Sep 08, 2011 |
not rated yet |
0
-
Lymphocyte count indicates the prognosis of patients with renal cell carcinoma
Jun 01, 2011 |
not rated yet |
0
-
Cancer vaccine combination therapy shows survival benefit in breast cancer
May 15, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
8 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Low radiation scans help identify cancer in earliest stages
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer
11 minutes ago |
not rated yet |
0
Poliovirus vaccine trial shows early promise for recurrent glioblastoma
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer
1 hour ago |
not rated yet |
0
Racial disparities in the surgical management of non-small cell lung cancer
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer
5 hours ago |
not rated yet |
0
Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients ...
Cancer
6 hours ago |
not rated yet |
0
New tumour-killer shows great promise in suppressing cancers
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
Cancer
6 hours ago |
5 / 5 (1) |
0
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Genetic variation among patients with pulmonary fibrosis associated with improved survival
Variation in the gene MUC5B among patients with idiopathic pulmonary fibrosis was associated with improved survival, according to a study published online by JAMA. The study is being released early online to coincide with i ...
Genetic risk for obesity found in many Mexican young adults
As many as 35 percent of Mexican young adults may have a genetic predisposition for obesity, said a University of Illinois scientist who conducted a study at the Universidad Autónoma de San Luis Potosί.
Shorter duration steroid therapy may offer similar effectiveness in reducing COPD exacerbations
Among patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) requiring hospital admission, a 5-day glucocorticoid treatment course was non-inferior (not worse than) to a 14-day course with regard ...
Race and gender influence diagnosis of COPD
African-Americans are less likely than whites and women are more likely than men to have had a prior diagnosis of chronic obstructive pulmonary disease (COPD) regardless of their current disease severity, according to a new ...
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
Jul 31, 2012
Rank: not rated yet